Not All EPCAM Deletions Are Equal: Deletion Subtype and MSH2 Involvement Determine Cancer Risk in EPCAM-Associated Lynch Syndrome
CGA-IGC 2026
Kristin Kohler, Felicia Hernandez, Ashley P. L. Marsh, Carolyn Horton, John Ranola, Michael J Hall, Heather Hampel
Background and Aim
EPCAM (formally TACSTD1) is involved in cell-cell adhesion and signaling and is immediately upstream of MSH2 on chromosome 2. Gross germline deletions involving the 3’ end of EPCAM represent a distinct mechanism of Lynch syndrome (LS) pathogenesis through epigenetic silencing of the downstream MSH2 gene. However, the clinical implications of different EPCAM deletion subtypes remain incompletely characterized. This study aimed to compare cancer phenotypes across EPCAM deletion subtypes and MSH2 truncating variants to clarify cancer-specific risk patterns.
Methods
Individuals with EPCAM deletions or MSH2 truncating variants identified through multigene panel testing (MGPT) at a single diagnostic laboratory (2012-2025) were retrospectively evaluated. Four molecular cohorts were analyzed: 3’ EPCAM gross deletions (n=96), full EPCAM deletions (n=22), contiguous EPCAM-MSH2 deletions (n=180), and MSH2 nonsense/frameshift (ns/fs) variants (n=206). EPCAM deletion subtype was delineated by MLPA and/or microarray analysis. Cancer history, age at first cancer, cancer burden, and LS-associated cancer frequencies were compared across cohorts. Multivariable logistic regression adjusted for age, sex at birth, and race/ethnicity used MGPT-negative individuals as the reference.
Results
Clinical severity followed a gradient across molecular cohorts. Mean cancer burden increased progressively from full EPCAM deletions (0.45 cancers/individual) to 3’ EPCAM gross deletions (0.82), contiguous EPCAM-MSH2 deletions (1.17), and MSH2 truncating variants (1.22)(MGPT-negative controls: 0.68). Compared with an MGPT-negative cohort, full EPCAM deletion carriers showed no significant enrichment of LS-associated cancers, whereas 3’ EPCAM deletion carriers exhibited a predominantly colorectal cancer phenotype (OR 16.82, p<0.0001), consistent with tissue-specific MSH2 epigenetic silencing driven by active EPCAM transcription. Contiguous EPCAM-MSH2 deletions demonstrated elevated risks of colorectal, endometrial, ovarian, and LS-associated cancers, mirroring MSH2 truncating variants.
Conclusions
Cancer risk and tumor spectrum vary by EPCAM deletion subtype and extent of MSH2 involvement. Incorporating deletion subtype into clinical interpretation may improve risk stratification and surveillance recommendations for individuals with gross deletions involving EPCAM.
Related publications